Education
About Us
Working with TipRanks
Follow Us
VistaGen Therapeutics (VTGN)
NASDAQ:VTGN
Earnings Data
Report Date
Jul 01, 2026TBA (Confirmed)
Period Ending
2026 (Q4)Consensus EPS Forecast
-0.32Last Year’s EPS
-0.47Same Quarter Last Year
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presented a balanced mix of progress and uncertainty. Positive elements include completion of PALISADE-3 randomized portion, PALISADE-4 enrollment on track, active open-label extensions, focused operational improvements, an AI/ML-driven analytic program, USAN adoption of refisolone with an IND planned in H1 2026, and $61.8M in reported cash with cost-control measures. Negative elements center on a higher placebo response in PALISADE-3 that necessitates additional analysis and operational remediation, unresolved efficacy clarity from top-line data, potential SAP modifications that would require FDA resubmission, reliance on exploratory AI/ML methods with no guarantees, and limited disclosure on financial runway timing. Given the roughly balanced number of material positives and material uncertainties, the overall tone is cautiously neutral.Company Guidance
Completion of PALISADE-3 Randomized Portion
The company completed the randomized portion of the PALISADE-3 Phase III trial in social anxiety disorder as guided and is analyzing results to inform PALISADE-4 and broader program strategy.
PALISADE-4 Enrollment On Track
PALISADE-4 (Phase III) enrollment and randomized portion remain ongoing and are reported to be on track with prior guidance; the open-label extension portions of PALISADE-3 and PALISADE-4 also remain active.
Advanced Analytical Work Using AI/ML
The company engaged third-party collaborators to apply proprietary AI and machine learning across PALISADE studies to identify nonspecific/placebo responses, potential predictors of drug response, and candidate covariates for enhanced statistical models.
Operational Enhancements Implemented
Following PALISADE-3, Vistagen implemented moderate refinements including retraining, site rationalization, centralized recruitment focus, audio monitoring and other placebo-mitigation operational measures for PALISADE-4.
Refisolone (PH80) USAN Adoption and IND Plans
PH80 received an official USAN adoption (refisolone). The company plans to submit a U.S. IND in the first half of 2026 to support potential Phase II development for moderate to severe vasomotor symptoms, building on a completed Phase IIa in Mexico that showed clinical benefit.
Cash Position and Cost Controls
As of December 31, 2025, Vistagen reported $61.8 million in cash, cash equivalents and marketable securities and implemented company-wide cash preservation measures to extend runway and enhance operational efficiency.
No Observable Enrollment Impact from PALISADE-3 Announcement
Management reported no discernible negative impact on PALISADE-4 enrollment rates after the December 17 public announcement regarding PALISADE-3 results.
Clarification on Share Count Disclosure
Management clarified end-of-quarter shares outstanding were 39.7 million versus a weighted average of 42.0 million for the quarter, noting the difference reflects prefunded warrants used in EPS calculations.
VTGN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
VTGN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 12, 2026 | $0.55 | $0.51 | -7.34% |
Nov 13, 2025 | $3.80 | $3.80 | 0.00% |
Aug 07, 2025 | $2.73 | $2.97 | +8.79% |
Jun 17, 2025 | $2.38 | $2.06 | -13.45% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does VistaGen Therapeutics (VTGN) report earnings?
VistaGen Therapeutics (VTGN) is schdueled to report earning on Jul 01, 2026, TBA (Confirmed).
What is VistaGen Therapeutics (VTGN) earnings time?
VistaGen Therapeutics (VTGN) earnings time is at Jul 01, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VTGN EPS forecast?
VTGN EPS forecast for the fiscal quarter 2026 (Q4) is -0.32.